Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS

Area of Science:

• Neuroscience
• Pharmacology
• Cell Biology

Background:

• Oxidative stress and inflammation are key in Parkinson's disease (PD) progression.
• The brain has a local angiotensin system, with Angiotensin II (AII) implicated in inflammation and oxidative stress.

Purpose of the Study:

• To investigate the role of Angiotensin II (AII) in 6-hydroxydopamine (6-OHDA)-induced dopaminergic (DA) neurodegeneration in Parkinson's disease models.
• To determine the involvement of AT1 receptors and glial cells in AII-mediated neuroinflammation and oxidative stress.

Main Methods:

• Primary rat mesencephalic cultures treated with 6-OHDA and AII.
• Assessment of DA cell death, superoxide generation, NADPH-oxidase mRNA expression, and microglial activation.
• In vivo studies using rats with 6-OHDA-induced PD models treated with AT1 antagonists.

Main Results:

• AII significantly increased 6-OHDA-induced DA cell death, superoxide generation in neurons and glia, and microglial activation.
• These detrimental effects were reversed by AT1 antagonists, NADPH inhibitors, or glial cell elimination.
• In vivo AT1 antagonist treatment reduced 6-OHDA-induced DA cell loss and microglial activation.

Conclusions:

• AII, acting through AT1 receptors, exacerbates dopaminergic neurodegeneration in PD by enhancing neuroinflammation and oxidative stress.
• Glial cells play a critical role in mediating the neurotoxic effects of AII in the context of Parkinson's disease.